Literature DB >> 16702896

Evaluating rater competency for CNS clinical trials.

Steven D Targum1.   

Abstract

Clinical trials rely on ratings accuracy to document a beneficial drug effect. This study examined rater competency with clinical nervous system rating instruments relative to previous clinical experience and participation in specific rater training programs. One thousand two hundred forty-one raters scored videotaped interviews of the Hamilton Anxiety Scale (HAM-A), Hamilton Depression Scale (HAM-D), and Young Mania Rating Scale (YMRS) during rater training programs conducted at 9 different investigator meetings. Scoring deviations relative to established acceptable scores were used to evaluate individual rater competency. Rater competency was not achieved by clinical experience alone. Previous clinical experience with mood-disordered patients ranged from none at all (18%) to 40 years in 1 rater. However, raters attending their first-ever training session (n = 485) were not differentiated on the basis of clinical experience on the HAM-A (P = 0.054), HAM-D (P = 0.06), or YMRS (P = 0.66). Alternatively, participation in repeated rater training sessions significantly improved rater competency on the HAM-A (P = 0.002), HAM-D (P < 0.001), and YMRS (P < 0.001). Furthermore, raters with clinical experience still improved with rater training. Using 5 years of clinical experience as a minimum cutoff (n = 795), raters who had participated in 5 or more training sessions significantly outperformed comparably experienced raters attending their first-ever training session on the HAM-A (P = 0.003), HAM-D (P < 0.001), and YMRS (P < 0.001). The findings show that rater training improves rater competency at all levels of clinical experience. Furthermore, more stringent criteria for rater eligibility and comprehensive rater training programs can improve ratings competency.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16702896     DOI: 10.1097/01.jcp.0000219049.33008.b7

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  10 in total

Review 1.  Alzheimer's disease drug development in 2008 and beyond: problems and opportunities.

Authors:  Robert E Becker; Nigel H Greig
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

2.  Rater Training for a Multi-Site, International Clinical Trial: What Mood Symptoms may be most Difficult to Rate?

Authors:  Martha Sajatovic; Richa Gaur; Curtis Tatsuoka; Susan De Santi; Nathan Lee; Judith Laredo; Sulabh Tripathi
Journal:  Psychopharmacol Bull       Date:  2011-09-15

3.  Ratings surveillance and reliability in a study of major depressive disorder with subthreshold hypomania (mixed features).

Authors:  Steven D Targum; J Cara Pendergrass; Sang Lee; Antony Loebel
Journal:  Int J Methods Psychiatr Res       Date:  2018-06-26       Impact factor: 4.035

4.  Research staff training in a multisite randomized clinical trial: Methods and recommendations from the Stimulant Reduction Intervention using Dosed Exercise (STRIDE) trial.

Authors:  Robrina Walker; David W Morris; Tracy L Greer; Madhukar H Trivedi
Journal:  Addict Res Theory       Date:  2014

Review 5.  Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?

Authors:  Robert E Becker; Nigel H Greig; Ezio Giacobini
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

6.  Web-based training and interrater reliability testing for scoring the Hamilton Depression Rating Scale.

Authors:  Jules Rosen; Benoit H Mulsant; Patricia Marino; Christopher Groening; Robert C Young; Debra Fox
Journal:  Psychiatry Res       Date:  2008-08-30       Impact factor: 3.222

Review 7.  Redefining affective disorders: relevance for drug development.

Authors:  Steven D Targum; Mark H Pollack; Maurizio Fava
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

Review 8.  Alzheimer's disease drug development: old problems require new priorities.

Authors:  Robert E Becker; Nigel H Greig
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-12       Impact factor: 4.388

9.  Pilot test of an online training module on near-infrared spectroscopy monitoring for the randomised clinical trial SafeBoosC-III.

Authors:  Mathias Lühr Hansen; Marie Isabel Rasmussen; Snorre Rubin; Adelina Pellicer; Guoqiang Cheng; Xin Xu; Yin Zhaoqing; Vibeke Zoffmann; Gorm Greisen
Journal:  Trials       Date:  2020-04-23       Impact factor: 2.279

10.  Audio-digital recordings for surveillance in clinical trials of major depressive disorder.

Authors:  Steven D Targum; Christopher J Catania
Journal:  Contemp Clin Trials Commun       Date:  2019-01-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.